Divestiture

Lobbying spending shattered records at $5.3 billion in 2025, driven by battles over trade, taxes, AI, and a surge in Trump-aligned influence firms.

A proposed $108.5M FDA funding boost aims to modernize infant formula rules, paving the way for plant-based options and a more secure supply chain.

ASIC reports a smaller loss but slumping revenue as it sells key NYC properties. With low cash and NYSE warnings, is this a survival plan or a fire sale?

On a day celebrating his legacy, Bruno Mars donated $1 million to a future Nevada children's hospital, spotlighting a critical healthcare crisis.

After three decades of talks, legislation for the K'ómoks First Nation's modern treaty promises self-governance but faces opposition from neighbours.

A federal judge has denied Binance and its ex-CEO's attempt to force arbitration, allowing a billion-dollar securities class action to proceed in court.

The Alaska Native corporation's spring distribution highlights a unique model where financial success directly fuels cultural vitality and environmental restoration.

Stepping into the role of Chairman and CEO, Dianne Taube ushers in a new era for the influential foundation with a focus on innovation and measurable impact.

A major US mutual life insurer is launching a Bermuda reinsurer with Agam Capital's help, highlighting a trend of using tech to optimize capital offshore.

GoldenTree's oversubscribed $3B fund close highlights a major shift as institutional investors seek flexible, high-yield private credit strategies.

With promising Phase 2 data for its novel peptide therapies, Sapience Therapeutics is engaging investors, signaling a critical push for future growth.

Italian infrastructure giant Mundys can now own nearly 30% of Getlink, a key move in European transport that passed the UK's strict security review.

A jury found Abbott's Similac caused a fatal gut disease in premature infants, igniting a legal firestorm over what the formula giant knew and when.

A Chicago jury found Abbott liable for infants' injuries from Similac, adding to a wave of lawsuits over the deadly intestinal disease NEC.

The diagnostics firm posts strong 2025 growth, but the impending loss of a key partner puts its high-stakes strategic pivot squarely to the test.

A new IP firm, led by an industry veteran, acquired 500+ Avaya networking patents. The move signals a new era for tech licensing and innovation.

Lupin has launched a generic version of the blockbuster diabetes drug Farxiga, signaling lower costs for patients and a major shake-up in the SGLT2 market.

A court ruling dismisses a lawsuit against Montclair's Lackawanna Plaza plan, clearing the path for the long-stalled, transformative project to proceed.

An investigation into a Florida 'trash school' reveals a national crisis of toxic dumps near schools, disproportionately harming children of color.

As drug-resistant superbugs threaten modern medicine, a novel liquid therapeutic from Seres Therapeutics offers a lifeline for the most vulnerable patients.